Our findings align with observations from other studies indicating that SKA3 overexpression predicts poor prognosis and is significantly associated with OS in PDAC [15] as well as with OS, disease-specific survival, and disease-free interval in PAAD [14]. This evidence concerns the gene SKA3 and pancreatic adenocarcinoma.